A higher overall number of genetic alterations in cell-free circulating tumor DNA (ctDNA) were associated with worse treatment outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC), according to a study that will be presented at the 2017 Genitourinary Cancers Symposium.1
Because cell-free ctDNA, tumor DNA that circulates freely in patients’ bloodstreams, may play a prognostic role and evolve during therapy, researchers sought to profile the ctDNA of patients with mCRPC and evaluate their association with clinical outcomes and evolution of therapy.
For the study, investigators tested 514 patients with advanced prostate cancer for potentially targetable alterations using a commercially available “liquid biopsy” test called Guardant360 prior to receiving new systemic therapy and analyzed data on clinical factors, current and prior therapy, time-to-treatment failure, and survival from 163 patients.
Results showed that 94% of patients had at least 1 ctDNA alteration. The most common recurrent somatic mutations were in TP53 (36% of patients); AR (22%); APC (10%); NF1 (9%); EGFR, CTNNB1, and ARID1A (6% each); and BRCA1, BRCA2, and PIK3CA (5% each).
The most common genes with increased copy numbers, which can lead to an overabundance of proteins that drive cancer growth, were AR (30%), MYC (20%) and BRAF (18%).
Among the 163 patients evaluated for associations between gene alterations and outcomes, 28.8% had not received treatment for mCRPC. Investigators found that a higher number of ctDNA alterations, including AR alterations, was associated with significantly shorter time-to-treatment failure (hazard ratio [HR], 1.05; P = .026).
Investigators also observed a trend toward shorter time-to-treatment failure (HR, 1.42; P = .053) and overall survival (HR, 2.51; P = .09).
In patients who underwent periodic blood tests during treatment, investigators detected significantly more new alterations in AR compared with treatment-naive patients (56% vs 37%; P = .028), suggesting that targeted AR gene mutations may be a promising treatment strategy.
“This circulating tumor DNA test is now a valuable research tool to discover new molecular targets,” lead study author Guru Sonpavde, MD, an associate professor of medicine at the University of Alabama in Birmingham, AL, said in a press release. “Eventually, it may also serve as a non-invasive alternative to the traditional tumor biopsy in cases where tissue biopsy is not safe or feasible.”
RELATED: Explaining Androgen Receptor-indifferent Prostate Cancer
Further controlled, prospective clinical trials are needed to confirm whether selecting treatment based on the molecular information provided by this blood test improves clinical outcomes.
- Blood test uncovers potential new treatment targets in advanced prostate cancer [news release]. Alexandria, VA: American Society of Clinical Oncology (ASCO); February 13, 2017. Accessed February 13, 2017.
This article originally appeared on Cancer Therapy Advisor